DOI QR코드

DOI QR Code

Expression of EGFR and p53 in Head and Neck Tumors among Sudanese Patients

  • Abusail, Mustafa Saadalnour (Department of Histopathology and Cytology, Faculty of Medical laboratory Sciences, Elneelain University) ;
  • Dirweesh, Ahmed Mohmed Ahmed (Medicine, University of Hail, Kingdom of Saudi Arabia) ;
  • Salih, Rashid Awad Abdalla (Medicine, University of Hail, Kingdom of Saudi Arabia) ;
  • Gadelkarim, Ahmed Hussain (Medicine, University of Hail, Kingdom of Saudi Arabia)
  • Published : 2013.11.30

Abstract

Background: The aim of this study was to assess EGFR and p53 expression in head and neck tumors among Sudanese patients using immunohistochemistry. Materials and Methods: A retrospective descriptive study was performed on 150 samples from patients diagnosed with HNCs as well as 50 from individuals with benign head and neck tumors. EGFR and p53 expression was assessed using immunohistochemistry (IHC). Results: EGFR was expressed in 126/150 (84%) of HNCS and 6/50 (12%) benign head and neck tumors where as p53 was expressed in 29/150 (19.3%) of HNCs and 2/50 (4%) of benign head and neck tumors, with significance at p values of 0.001 and 0.009 respectively. Conclusions: There is a significant association between EGFR, P53 expression and head and neck cancers among Sudanese patients.

Keywords

Head and neck cancer;Sudanese;EGFR;p53

References

  1. Andl T, Kahn T, Pfuhl A, et al (1998). Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res, 58, 5-13.
  2. Benard J, Douc-Rasy S, Ahomadegbe JC (2003). TP53 family members and human cancers. Hum Mutat, 21, 182-91. https://doi.org/10.1002/humu.10172
  3. Bonner JA, Harari PM, Giralt J, et al (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. NEnglJ Med, 354, 567-578. https://doi.org/10.1056/NEJMoa053422
  4. Brachman DG, Graves D, Vokes E, et al (1992). Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res, 52, 4832-3.
  5. Calzolari A, Chiarelli I, Bianchi S, et al (1997). Immunohistochemical vs molecular biology methods. Complementary techniques for effective screening of p53 alterations in head and neck cancer. Am J Clin Pathol, 107, 7-11. https://doi.org/10.1093/ajcp/107.1.7
  6. Chung CH, Gillison ML (2009) Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res, 15, 6758-62. https://doi.org/10.1158/1078-0432.CCR-09-0784
  7. Chung CH, Ely K, McGavran L (2006). Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clinical Oncol, 24, 4170-6. https://doi.org/10.1200/JCO.2006.07.2587
  8. Ciardiello F, Tortora G (2003). Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer, 39, 1348-54. https://doi.org/10.1016/S0959-8049(03)00235-1
  9. Egloff AM, Grandis J (2006). Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma. Expert Opin Ther Targets. 10, 639-47. https://doi.org/10.1517/14728222.10.5.639
  10. Fakhry C, Westra WH, Li S (2008). Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J National Cancer Institute, 100, 261-9. https://doi.org/10.1093/jnci/djn011
  11. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  12. Santarelli A, Lo Russo L, Bambini F, Campisi G, Lo Muzio L (2009). New perspectives in medical approach to therapy of head and neck squamous cell carcinoma. Minerva Stomatol, 58, 445-52.
  13. Gallo O, Bianchi S, Giovannucci-Uzzielli ML, et al (1995). p53 oncoprotein overexpression correlates with mutagen-induced chromosome fragility in head and neck cancer patients with multiple malignancies. Br J Cancer, 71, 1008-12. https://doi.org/10.1038/bjc.1995.194
  14. Gallo O, Bianchi S (1995). p53 expression: a potential biomarker for risk of multiple primary malignancies in the upper aerodigestive tract. Eur J Cancer B Oral Oncol, 31, 53-7. https://doi.org/10.1016/0964-1955(94)00031-X
  15. Gillison ML, Shah KV (2001). Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol, 13, 183-8. https://doi.org/10.1097/00001622-200105000-00009
  16. Goon PK, Stanley MA, Ebmeyer J, et al (2009). HPV & head and neck cancer: a descriptive update. Head Neck Oncol, 1, 36. https://doi.org/10.1186/1758-3284-1-36
  17. Grandis JR, Chakraborty A, Melhem MF(1997). Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene, 15, 409-16. https://doi.org/10.1038/sj.onc.1201188
  18. Grandis JR, Chakraborty A, Zeng Q (1998). Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem, 69, 55-62. https://doi.org/10.1002/(SICI)1097-4644(19980401)69:1<55::AID-JCB6>3.0.CO;2-U
  19. Grandis JR, Chakraborty A, Zeng Q (1980). Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem, 69, 55-62.
  20. Grandis JR, Sok JC (2004). Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther, 102, 37-46. https://doi.org/10.1016/j.pharmthera.2004.01.002
  21. Grandis JR, Tweardy DJ (1993). Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res, 53, 3579-84.
  22. Grandis JR, Zeng Q, Tweardy DJ (1996). Retinoic acid normalizes the increased gene transcription rate of TGF- alpha and EGFR in head and neck cancer cell lines. Nat Med, 2, 237-40. https://doi.org/10.1038/nm0296-237
  23. Helton ES, Chen X (2007). p53 modulation of the DNA damage response. J Cell Biochem, 100, 883-96. https://doi.org/10.1002/jcb.21091
  24. Hoffmann TK, Schirlau K, Sonkoly E, et al (2009). A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int J Cancer, 124, 2589-96. https://doi.org/10.1002/ijc.24269
  25. Homann N, Nees M, Conradt C, et al (2001). Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma. Clin Cancer Res, 7, 290-6.
  26. Knowles LM, Stabile LP, Egloff AM, et al (2009). HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res, 15, 3740-50. https://doi.org/10.1158/1078-0432.CCR-08-3252
  27. Kumar B, Cordell KG, Lee JS (2008). EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol, 26, 3128-37. https://doi.org/10.1200/JCO.2007.12.7662
  28. Lassen P (2010). The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol, 3, 371-80.
  29. Lee JW, Soung YH, Kim SY (2005). Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res, 11, 2879-82. https://doi.org/10.1158/1078-0432.CCR-04-2029
  30. Lukas J, Lukas C, Bartek J (2004). Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair, 3, 997-1007. https://doi.org/10.1016/j.dnarep.2004.03.006
  31. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 2, 74-108.
  32. Pu YS, Huang CY, Kuo YZ, et al (2009). Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma. J Biomed Sci, 16, 127-32.
  33. Rischin D, Young R, Fisher R (2009). Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. J Clin Oncol, 27, 6004.
  34. Sarkis SA, Abdullah BH, Abdul Majeed BA, Talabani NG (2010). Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol, 25, 13.
  35. Sherr CJ, McCormick F (2002). The RB and p53 pathways in cancer. Cancer Cell, 2, 103-12. https://doi.org/10.1016/S1535-6108(02)00102-2
  36. Smith EM, Rubenstein LM, Hoffman H, Haugen TH, Turek LP (2010). Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer. Infect Agent Cancer, 5, 4. https://doi.org/10.1186/1750-9378-5-4
  37. Smith EM, Wang D, Kim Y, et al (2008). P16INK4a expression, human papillomavirus, and survival in head and neck cancer. Oral Oncol, 44, 133-42. https://doi.org/10.1016/j.oraloncology.2007.01.010
  38. Soulieres D, Senzer NN, Vokes EE, et al (2004). Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol, 22, 77-85. https://doi.org/10.1200/JCO.2004.06.075
  39. Temam S, Kawaguchi H, El-Naggar AK, et al (2007). Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol, 25, 2164-70. https://doi.org/10.1200/JCO.2006.06.6605

Cited by

  1. Association of Cyclin D1 Variants with Head and Neck Cancer Susceptibility: Evidence from a Meta-analysis vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5645
  2. Relationship between EGFR Over-expression and Clinicopathologic Characteristics in Squamous Cell Carcinoma of the Esophagus: A Meta-analysis vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5889
  3. Crosstalk between EGFR and p53 in Hepatocellular Carcinoma vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8069
  4. DOX-MTX-NPs Augment p53 mRNA Expression in OSCC Model in Rat: Effects of IV and Oral Routes vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8377
  5. New formulated "DOX-MTX-loaded Nanoparticles" Down-regulate HER2 Gene Expression and Improve the Clinical Outcome in OSCCs Model in Rat: the Effect of IV and Oral Modalities vol.15, pp.21, 2014, https://doi.org/10.7314/APJCP.2014.15.21.9355
  6. Effect of vascular endothelial growth factor siRNA and wild-type p53 co-expressing plasmid in MDA-MB-231 cells vol.13, pp.1, 2015, https://doi.org/10.3892/mmr.2015.4571
  7. Hesa-A Improves Clinical Outcome of Oral Carcinoma by Affecting p53 Gene Expression in vivo vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4169
  8. Hesa-A Down-Regulates erb/b2 Oncogene Expression and Improves Outcome of Oral Carcinoma in a Rat Model vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6947
  9. Immunohistochemical Expression of Cytokeratins and Epithelial Membrane Protein 2 in Nasopharyngeal Carcinoma and its Potential Implications vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.653
  10. Clinicopathologic Aspects of Squamous Cell Carcinoma of the Uterine Cervix: Role of PTEN, BCL2 and P53 vol.8, pp.11, 2018, https://doi.org/10.3390/app8112124